Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
A company is trying to unlock a key to aging, in a long-overlooked body part - 2Instructions to Pick the Best Album Rates for Your Investment funds
- 3The Way to Business: Startup Illustrations Learned
- 4Canada cancels its 1st moon rover: 'It's hopefully not a lost cause'
- 5Was This Driver Simply Having A great time Or Behaving Like An Ass?
- Israel's Druze use AI to present to UN testimonies of 'sexual terrorism' against Syrian Druze women
- Putin, Netanyahu discuss Middle East in phone call, Kremlin says
- Eight wounded, cars catch fire in central Israel following strike from Iranian cluster munition
- Photos: Presidential turkey pardons — a look back
- Airbnb Unveils Airport Pickup Service Across 125 Cities in Global Expansion
- Share your number one city visit transport that leaves a mark on the world wake up!
- Former hostage Eitan Mor on Hamas: ‘They will not give up until the last Israeli is gone'
- Innospace's rocket crashes in first commercial launch in Brazil; shares tumble
- Defence chiefs of Thailand and Cambodia to discuss ceasefire
